Investigation of the efficacy of ranibizumab BS and other anti-VEGF drugs for macular edema associated with branch retinal vein occlusion

Investigation of the efficacy of ranibizumab BS and other anti-VEGF drugs for macular edema associated with branch retinal vein occlusion - Investigation of the efficacy of ranibizumab BS and other anti-VEGF drugs for macular edema associated with branch retinal vein occlusion

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056284

Enrollment

Registered

2024-11-27

Start date

2024-11-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch retinal vein occlusion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed with branch retinal vein occlusion and used anti-VEGF agents for the first time among the outpatients of the Department of Ophthalmology, Fukushima Medical University from August 2013 to September 2024.

Exclusion criteria

Exclusion criteria: 1 Patients who have refused the use of their medical information for research 2 Patients who have had subjective symptoms for more than 6 months since the onset of symptoms 3 Patients with diabetic retinopathy in the evaluable eye 4 Patients who have already undergone laser photocoagulation of the evaluable eye prior to the use of anti-VEGF agents 5 Patients who have received subcapsular tenon or intravitreal injections of steroids in the evaluable eye within 60 days prior to the start of anti-VEGF therapy

Design outcomes

Primary

Measure	Time frame
Change over time in exudative lesions up to 2 months after ranibizumab BS treatment (percentage of dry macula achieved)	—

Countries

Japan

Contacts

Public ContactTetsuju Sekiryu

Fukushima Medical University Department of Ophthalmology

sekiryu@fmu.ac.jp0245471303

Outcome results